Evidence map›Paper›PMID 35469122›Full record

ArticleBulletin of the National Research Centre2022

Evaluation of respiratory tract bacterial co-infections in SARS-CoV-2 patients with mild or asymptomatic infection in Lagos, Nigeria.

Olabisi Flora Davies-Bolorunduro, Muinah Adenike Fowora, Olufemi Samuel Amoo, Esther Adeniji, Kazeem Adewale Osuolale, Oluwatobi Oladele, Tochukwu Ifeanyi Onuigbo, Josephine Chioma Obi, Joy Oraegbu, Oluwatobi Ogundepo and 8 more

Open access · diamondAbstract read
In one paragraph

Article in Bulletin of the National Research Centre, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Effect of nasal carriage ofMicrobiology spectrum · 2024
    Article
  4. Extracts ofPharmaceutical biology · 2023
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Olabisi Flora Davies-BolorunduroMicrobiology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.ORCID 0000-0002-9783-9739
Muinah Adenike FoworaMolecular Biology and Biotechnology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
Olufemi Samuel AmooMicrobiology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
Esther AdenijiMicrobiology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
Kazeem Adewale OsuolaleMonitoring and Evaluation Unit, Nigerian Institute of Medical Research, Lagos, Nigeria.
Oluwatobi OladeleMolecular Biology and Biotechnology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
Tochukwu Ifeanyi OnuigboMicrobiology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
Josephine Chioma ObiMicrobiology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
Joy OraegbuMicrobiology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
Oluwatobi OgundepoMicrobiology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
Rahaman Ademolu AhmedMicrobiology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
Olagoke AbdulRazaq UsmanFederal Medical Centre, Ebute-Metta, Lagos, Nigeria.
Bosede Ganiyat IyapoFederal Medical Centre, Ebute-Metta, Lagos, Nigeria.
Adedamola Adejuwon DadaFederal Medical Centre, Ebute-Metta, Lagos, Nigeria.
Ngozi OnyiaPaelon Memorial Hospital, Lagos, Nigeria.
Richard Adebayo AdegbolaMicrobiology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
Rosemary Ajuma AuduMicrobiology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
Babatunde Lawal SalakoMicrobiology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
Nigerian Institute of Medical Research · NGFederal Medical Centre · NGLagos State Health Service Commission · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: A common complication of any respiratory disease by a virus could be a secondary bacterial infection, which is known to cause an increase in severity. It is, however, not clear whether the presence of some opportunistic pathogens called pathobionts contributes to the severity of the disease. In COVID-19 patients, undetected bacterial co-infections may be associated with the severity of the disease. Therefore, we investigated the implications of bacterial co-infections in COVID-19 cases. Results: This is a cross-sectional study that involved archived specimens collected from nasopharyngeal samples of 150 people for COVID-19 screening in Lagos. DNA extraction from the samples was carried out to determine the presence of five respiratory bacterial pathogens using nested real-time PCR, and data were analysed using the Chi-square test. Of the 150 samples collected, 121 (80.7%) were positive for SARs-CoV-2 infection and 29 were negative. The proportion of patients with bacteria co-infection in COVID-19-negative, asymptomatic, and mild cases were 93.1%, 70.7%, and 67.5%, respectively. There was no statistically significant difference between mild COVID-19 conditions and bacteria co-infection ( Conclusions: The current study shows that bacterial co-infection and superinfection with COVID-19 are not associated with mild and asymptomatic COVID-19 cases in our setting. However, given the high prevalence of

Indexed as

Bacterial pathogensCo-infectionCOVID-19SARS-CoV-2Severity

Identifiers

PMID35469122
PMCPMC9022018
OpenAlexW4224217834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.